Acadia Pharmaceuticals’ stock prices went up by more than 10 percent again because of a promising new drug

At the auction on June 15, the price of Acadia Pharmaceuticals Inc. (ACAD) shares went up by 15.51 percent to $18.77. This was due to the release of official data. The US Food and Drug Administration (FDA) has released documents that may show that the results of experiments using the drug Nuplazid to treat psychosis in Alzheimer’s disease patients were good.

Remember that the drug Nuplazid caused stock prices to rise by more than 10% in 2019. Alzheimer’s disease and at least its worst symptoms have a huge unmet need for treatment. Because of this, investors are very interested in any potential drugs that show a strong positive effect. Nuplazid has already been approved as a drug, and it brings in almost $500 million a year for Acadia Pharmaceuticals.

It is approved to treat psychoses in people with Parkinson’s disease, but Acadia Pharmaceuticals wants to use it to treat psychoses in other diseases that are similar to Parkinson’s. Theoretically, Nuplazid can be used to treat a wide range of conditions, from psychoses caused by Alzheimer’s disease and schizophrenia to mood disorders. Acadia Pharmaceuticals has the only drug that has been approved, so it makes sense that the company is trying to get more people to use it.

But this is hard to do. Last year, the FDA said that there wasn’t enough proof that Nuplazid worked to approve it as a treatment for psychosis in Alzheimer’s patients. Later, the company sent the FDA new research results. The information that has been made public shows at least that the government is ready to look at the experimental data.